Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences, Inc. (RNA) EBITDA Margin (2019 - 2025)

Avidity Biosciences' EBITDA Margin history spans 7 years, with the latest figure at 27477.56% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 2389676.0% year-over-year to 27477.56%; the TTM value through Dec 2025 reached 3652.2%, down 71996.0%, while the annual FY2025 figure was 3652.2%, 71998.0% down from the prior year.
  • EBITDA Margin reached 27477.56% in Q4 2025 per RNA's latest filing, down from 1398.4% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 881.73% in Q1 2021 to a low of 27477.56% in Q4 2025.
  • Average EBITDA Margin over 5 years is 3720.38%, with a median of 2085.23% recorded in 2023.
  • The largest YoY upside for EBITDA Margin was 171987bps in 2025 against a maximum downside of -2389676bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 2090.93% in 2021, then rose by 14bps to 1795.09% in 2022, then tumbled by -48bps to 2664.84% in 2023, then crashed by -34bps to 3580.79% in 2024, then tumbled by -667bps to 27477.56% in 2025.
  • Per Business Quant, the three most recent readings for RNA's EBITDA Margin are 27477.56% (Q4 2025), 1398.4% (Q3 2025), and 4114.97% (Q2 2025).